Araris Biotech AG kicks-off with CHF2.5m s... Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting. more ➔
PharmaMar moves ahead with NDA for ZepsyreThe FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung … more ➔
Swedish researchers find new pain organResearchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts. more ➔
Researchers unravel potential cancer targe...British researchers have found out what’s going wrong with chromosome segregation in some cancers. more ➔
Pharming licenses orphan drug from Novarti...Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS more ➔
New stem cell population may help repair t... Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future. more ➔
Bayer bags iPSC specialist BlueRock Therap...Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics. more ➔
Liquid biopsy identifies residual breast c...Using a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients. more ➔
Novo Holdings puts $72m in LanzatechNovo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the companys sustainable fuels and chemicals platform more ➔
Google maps for tumours and organsGerman researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy. more ➔